---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262795"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:54:39.421600+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations

## Summary
- Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
- Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.
- Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.
- Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.
- Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated.

## SEC filing metadata
- accession: 0001193125-25-262795
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/0001193125-25-262795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262795
- JSON: https://secwatch.observer/filing/0001193125-25-262795.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.